Skip to main content
SENORES PHARMACEUTICALS LIMITED logo

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 54% confidence The document is an annual compliance disclosure under SEBI Regulation 31(4) regarding encumbrances on promoter shares, submitted to stock exchanges. It is not a financial report, earnings release, share‐issue, takeover or proxy solicitation, nor does it reflect a change in senior management. It is a routine regulatory filing required under Indian securities law. Therefore the best match is Regulatory Filings (RNS).
2026-04-22 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Audit Report / Information Classification · 90% confidence The document is a Reconciliation of Share Capital Audit Report under SEBI Regulations, dated April 6, 2026, and includes the actual audit findings (certification of share capital structure and demat details). It is a standalone audit report (not a full annual report, not merely an announcement). Accordingly, it fits the definition of an Audit Report / Information (AR). Q4 2026
2026-04-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms securities received from depository participants for dematerialisation during the quarter ended 31 March 2026. The document is a letter addressed to the Compliance Officer/Company Secretary of Senores Pharmaceuticals Limited, signed by a senior vice president of MUFG Intime India Private Limited. It contains no financial statements or substantive financial data, but rather a certification and confirmation related to securities dematerialisation. The document length is 2345 characters, which is short and consistent with a certification or confirmation letter rather than a full financial report. According to the Certification Rule, such a document should be classified as Regulatory Filings (RNS) rather than a financial report type.
2026-04-06 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a media release announcing a strategic joint venture by Senores Pharmaceuticals, Inc. in the United States. It is addressed to stock exchanges and references compliance with SEBI regulations for disclosure. The content focuses on the announcement of a new business partnership and strategic expansion, without containing any financial statements, detailed financial analysis, or regulatory filings such as annual or quarterly reports. The document is a public announcement of a corporate event rather than a detailed financial report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it relates to a strategic joint venture which is a form of capital or business expansion update.
2026-04-03 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces that the company's wholly owned subsidiary has formed a joint venture and subscribed to 70% membership interest in a new step-down subsidiary. The document provides details about the transaction, including the name of the new entity, the nature of the transaction, and regulatory references. There are no financial statements or detailed financial analysis present, and the document is primarily an announcement of a corporate action related to capital structure and subsidiary formation. This fits the category of Capital/Financing Update (CAP). The document length is 6214 characters, which is sufficient for a detailed announcement but does not contain a full financial report or earnings data. Therefore, the appropriate classification is CAP with high confidence.
2026-04-03 English
Allotment of Securities
Capital/Financing Update Classification · 95% confidence The document is an official communication from Senores Pharmaceuticals Limited to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting held on March 28, 2026. The key subject is the allotment of 1,170,000 warrants convertible into equity shares on a preferential basis. It references compliance with SEBI LODR Regulations and SEBI ICDR Regulations, which govern securities issuance and disclosures in India. The document includes detailed information about the preferential issue, allotment details, investor names, shareholding percentages pre- and post-issue, and pricing. This is a clear update on a capital raising event involving convertible warrants issued on a preferential basis, which fits the category of Capital/Financing Update (CAP). The document is not a full financial report, earnings release, or regulatory filing unrelated to capital changes. It is not a report publication announcement since it contains substantive details of the transaction itself. Therefore, the correct classification is CAP with high confidence.
2026-03-28 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.